Calbiotech and Liquid Biosciences Announce Strategic Collaboration

Partnership aims to accelerate development of next-generation diagnostic tests across multiple disease areas

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Calbiotech, Inc. and Liquid Biosciences have announced a strategic collaboration to accelerate the development and commercialization of advanced diagnostic tests. The partnership combines Calbiotech's assay development, regulated manufacturing, and global distribution capabilities with Liquid Biosciences' biomarker discovery and clinical innovation platform. The companies plan to rapidly translate promising biomarkers into scalable, real-world diagnostic solutions, with an initial focus on areas like neurodevelopmental disorders, oncology, and neurological health.

Why it matters

This collaboration brings together complementary strengths in diagnostic development, allowing the companies to more efficiently move promising science from biomarker identification to clinical deployment. By combining Calbiotech's manufacturing and commercialization expertise with Liquid Biosciences' biomarker discovery capabilities, the partnership aims to create a robust pipeline of differentiated diagnostic tests to address unmet medical needs across multiple disease areas.

The details

The collaboration is structured with a clear path toward forming a formal joint venture as programs mature. As an initial demonstration, the companies have commenced analytic development of an autism diagnostic assay, leveraging novel biomarkers discovered by Liquid Biosciences and Ignite Biomedical. Beyond the autism program, the joint roadmap includes upcoming efforts in prostate health, neurological diagnostics, and additional multiplex panels.

  • The strategic collaboration was announced on February 10, 2026.

The players

Calbiotech, Inc.

A U.S.-based diagnostics company specializing in assay development, regulated manufacturing, and global distribution of in vitro diagnostic products. Calbiotech recently expanded its capabilities with the addition of a CLIA-certified laboratory.

Liquid Biosciences

The leader in quantitative AI for diagnostics and biopharma, focused on reducing diagnostic test and drug development risk, time, and cost through its Emerge quantitative AI platform.

Ignite Biomedical

A company that collaborated with Liquid Biosciences on the discovery of novel biomarkers for Autism Spectrum Disorder.

Got photos? Submit your photos here. ›

What they’re saying

“This collaboration brings together complementary strengths. Liquid Biosciences is driving innovative biomarker discovery, while Calbiotech provides the regulated development, manufacturing scale, and commercial pathways needed to turn those discoveries into products. Together, we are building a discovery and development engine designed to move promising science efficiently from biomarker identification to clinical deployment.”

— David Barka, CEO of Calbiotech

“Calbiotech's deep experience in assay development and commercialization makes them an ideal partner. We are aligned on building a pipeline of differentiated diagnostics and creating a framework that supports long-term collaboration, including a future joint venture.”

— Patrick Lilley, Founder and CEO of Liquid Biosciences

What’s next

The companies plan to advance multiple programs in parallel while working toward formalizing their broader partnership structure. Additional announcements are expected as development milestones are reached.

The takeaway

This strategic collaboration combines the strengths of Calbiotech and Liquid Biosciences to create a robust pipeline of innovative diagnostic tests, with the potential to transform promising biomarker discoveries into scalable, clinically meaningful solutions across a variety of disease areas.